News und Analysen
Sonova HY 2025/26 Results: Strong sales and earnings growth in local currencies, outperforming the market
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
EQS-News: Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
EQS-News: Eckert & Ziegler Achieves Further Earnings Growth and Double-Digit Sales Growth in the Medical Segment
EQS-News: Formycon publishes nine-month results and confirms guidance – Pipeline progress and strong partnerships drive fiscal year 2025
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
ABIONYX Pharma Enters Advanced Strategic Discussions with IHU SEPSIS, the World’s First Center Dedicated to Sepsis
ABIONYX Pharma, (FR0012616852 - ABNX), a next-generation biotechnology company developing breakthrough therapies for severe and underserved diseases, today announced it has entered advanced
Bayer Launches “Science Delivers” Campaign Celebrating the Transformative Power of Science
Today, on World Science Day, Bayer is proud to launch its “Science Delivers” campaign, a nationwide initiative celebrating how science delivers answers, hope, and progress for all Americans—every
Dr. Judith Hartmann to Become New Chief Financial Officer of Bayer AG
The Supervisory Board of Bayer AG has appointed Dr. Judith Hartmann to the company’s Board of Management, effective March 1, 2026. She will succeed Wolfgang Nickl as the company’s Chief Financial
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Savara
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA).
Faruqi & Faruqi is a leading
KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease
Bayer today announced new Phase III investigational data from the pivotal FINE-ONE trial showing that KERENDIA® (finerenone) significantly reduced urine albumin-to-creatinine ratio (UACR) from
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
EQS-News: Heidelberg Pharma’s Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
EQS-News: MEDICLIN on track: business development in line with expectations
EQS-News: Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Ulcerative Colitis
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
EQS-News: Heidelberg Pharma to Present New Clinical Data of Lead ADC Candidate HDP-101 at the World ADC Congress 2025 and to Host Webinar
Dexcom Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2025.
Third Quarter 2025 Financial Highlights:
-
Revenue grew 22% year-over-year
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS)
EQS-News: Formycon invites to Conference Call on 2025 Nine-Month Results and announces Participation in Investor Conferences in the 4th Quarter of 2025
EQS-News: Immunic to Participate in Industry and Investor Conferences in November
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc